MX2023000382A - Inmunomoduladores heterocíclicos. - Google Patents
Inmunomoduladores heterocíclicos.Info
- Publication number
- MX2023000382A MX2023000382A MX2023000382A MX2023000382A MX2023000382A MX 2023000382 A MX2023000382 A MX 2023000382A MX 2023000382 A MX2023000382 A MX 2023000382A MX 2023000382 A MX2023000382 A MX 2023000382A MX 2023000382 A MX2023000382 A MX 2023000382A
- Authority
- MX
- Mexico
- Prior art keywords
- compound
- immunomodulator
- heterocyclic
- pharmaceutically acceptable
- acceptable salt
- Prior art date
Links
- 239000002955 immunomodulating agent Substances 0.000 title abstract 2
- 229940121354 immunomodulator Drugs 0.000 title abstract 2
- 230000002584 immunomodulator Effects 0.000 title abstract 2
- 125000000623 heterocyclic group Chemical group 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 3
- 150000003839 salts Chemical class 0.000 abstract 3
- 206010061218 Inflammation Diseases 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 150000002391 heterocyclic compounds Chemical class 0.000 abstract 1
- 208000026278 immune system disease Diseases 0.000 abstract 1
- 230000004054 inflammatory process Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5386—1,4-Oxazines, e.g. morpholine spiro-condensed or forming part of bridged ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/08—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/08—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/07—Optical isomers
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Dermatology (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Transplantation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202010633550.2A CN113896711A (zh) | 2020-07-06 | 2020-07-06 | 杂环类免疫调节剂 |
| PCT/CN2021/102873 WO2022007659A1 (zh) | 2020-07-06 | 2021-06-28 | 杂环类免疫调节剂 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2023000382A true MX2023000382A (es) | 2023-04-18 |
Family
ID=79186707
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2023000382A MX2023000382A (es) | 2020-07-06 | 2021-06-28 | Inmunomoduladores heterocíclicos. |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20230271933A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP4177247A4 (cg-RX-API-DMAC7.html) |
| JP (1) | JP7712703B2 (cg-RX-API-DMAC7.html) |
| KR (1) | KR20230037035A (cg-RX-API-DMAC7.html) |
| CN (2) | CN113896711A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2021303635A1 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3189041A1 (cg-RX-API-DMAC7.html) |
| MX (1) | MX2023000382A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2022007659A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2025522795A (ja) * | 2022-06-27 | 2025-07-17 | ピン セラピューティクス、インコーポレイテッド | カゼインキナーゼ1アルファを分解するための化合物及び方法 |
| JP2025531869A (ja) | 2022-09-09 | 2025-09-25 | イノヴォ セラピューティクス、インコーポレイテッド | CK1αおよびDUAL CK1α/GSPT1分解化合物 |
| EP4644382A4 (en) * | 2022-12-27 | 2026-04-01 | Gluetacs Therapeutics Shanghai Co Ltd | ISOINDOLINONE SKELETON-BASED COMPOUND WITH SULFUR/OXYGEN SUBSTITUTED GLUTARIMIDE AND ITS USE |
| WO2024222614A1 (zh) * | 2023-04-28 | 2024-10-31 | 北京诺诚健华医药科技有限公司 | 杂环类gspt1降解剂 |
| WO2025179161A1 (en) | 2024-02-21 | 2025-08-28 | Innovo Therapeutics, Inc. | Protein degrading compounds |
| WO2025195464A1 (zh) * | 2024-03-21 | 2025-09-25 | 上海惠康济民生物医药技术有限公司 | 取代的异吲哚啉类化合物、制备方法、药物组合物及应用 |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SG183257A1 (en) * | 2010-02-11 | 2012-09-27 | Celgene Corp | Arylmethoxy isoindoline derivatives and compositions comprising and methods of using the same |
| HK1211577A1 (en) | 2012-08-09 | 2016-05-27 | 细胞基因公司 | Processes for the preparation of (s)-3-4- ((4-(morpholinomethyl) benzyl)oxy)-1-oxoisoindolin-2-yl) piperidine-2,6-dione and pharmaceutically acceptable forms thereof |
| US9695145B2 (en) | 2013-01-22 | 2017-07-04 | Celgene Corporation | Processes for the preparation of isotopologues of 3-(4-((4- morpholinomethyl)benzyl)oxy)-1-oxoisoindolin-2-yl)piperidine-2,6-dione and pharmaceutically acceptable salts thereof |
| NZ731789A (en) * | 2014-10-30 | 2019-04-26 | Kangpu Biopharmaceuticals Ltd | Isoindoline derivative, intermediate, preparation method, pharmaceutical composition and use thereof |
| CA3000547C (en) * | 2015-09-29 | 2021-03-23 | Kangpu Biopharmaceuticals, Ltd. | Pharmaceutical composition comprising benzoheterocyclic compound and androgen receptor pathway modulator for prevention or treatment of prostate cancer |
| SI3526202T1 (sl) * | 2016-10-11 | 2025-04-30 | Arvinas Operations, Inc. | Spojine in postopki za ciljno razgradnjo androgenskih receptorjev |
| JP7062010B2 (ja) * | 2017-01-27 | 2022-05-02 | セルジーン コーポレイション | 3-(1-オキソ-4-((4-((3-オキソモルホリノ)メチル)ベンジル)オキシ)イソインドリン-2-イル)ピペリジン-2,6-ジオン及びそのアイソトポログ |
| JP7258009B2 (ja) * | 2017-07-10 | 2023-04-14 | セルジーン コーポレイション | 抗増殖化合物及びその使用方法 |
| US10513515B2 (en) | 2017-08-25 | 2019-12-24 | Biotheryx, Inc. | Ether compounds and uses thereof |
| SG11202003415XA (en) | 2017-10-18 | 2020-05-28 | Novartis Ag | Compositions and methods for selective protein degradation |
| CN107739389B (zh) | 2017-11-03 | 2020-03-31 | 华东师范大学 | 3位取代的(1-氧代异吲哚啉-2-基)哌啶-2,6-二酮类化合物及其合成方法 |
| IL278854B2 (en) * | 2018-05-23 | 2026-01-01 | Celgene Corp | Multiple myeloma treatment and biomarker use for 4-(4-(4-(((2-(6,2-dioxopyridin-3-yl)-1-oxoisoindolin-4-yl)oxy)methyl)benzyl)piperazin-1-yl-3-fluorobenzonitrile |
| WO2020023782A1 (en) * | 2018-07-27 | 2020-01-30 | Biotheryx, Inc. | Bifunctional compounds as cdk modulators |
| KR102947433B1 (ko) | 2019-04-12 | 2026-04-06 | 씨4 테라퓨틱스, 인코포레이티드 | 이카로스 및 아이올로스의 트리시클릭 분해제 |
-
2020
- 2020-07-06 CN CN202010633550.2A patent/CN113896711A/zh active Pending
-
2021
- 2021-06-28 US US18/014,623 patent/US20230271933A1/en active Pending
- 2021-06-28 KR KR1020237004029A patent/KR20230037035A/ko active Pending
- 2021-06-28 JP JP2023500425A patent/JP7712703B2/ja active Active
- 2021-06-28 CN CN202180048474.1A patent/CN115776983A/zh active Pending
- 2021-06-28 WO PCT/CN2021/102873 patent/WO2022007659A1/zh not_active Ceased
- 2021-06-28 MX MX2023000382A patent/MX2023000382A/es unknown
- 2021-06-28 CA CA3189041A patent/CA3189041A1/en active Pending
- 2021-06-28 AU AU2021303635A patent/AU2021303635A1/en active Pending
- 2021-06-28 EP EP21838438.6A patent/EP4177247A4/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| KR20230037035A (ko) | 2023-03-15 |
| JP2023533003A (ja) | 2023-08-01 |
| WO2022007659A1 (zh) | 2022-01-13 |
| CN115776983A (zh) | 2023-03-10 |
| CA3189041A1 (en) | 2022-01-13 |
| CN113896711A (zh) | 2022-01-07 |
| AU2021303635A1 (en) | 2023-02-09 |
| EP4177247A4 (en) | 2024-08-07 |
| JP7712703B2 (ja) | 2025-07-24 |
| US20230271933A1 (en) | 2023-08-31 |
| EP4177247A1 (en) | 2023-05-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NZ796075A (en) | Five-membered heteroaromatic imidazole compound and use thereof | |
| JOP20210001A1 (ar) | مشتقات 3-(5- هيدروكسي -1- أوكسو أيزو إندولين -2- يل) بيبريدين -2، 6- دايون واستخدامها لمعالجة أمراض مرتبطة ببروتين ذات أصبع الزنك من عائلة (ikaros 2 (ikzf2 | |
| PH12022551574A1 (en) | Egfr inhibitors | |
| MX2023010806A (es) | 1,2-dihidro-3h-pirazolo[3,4-d]pirimidin-3-onas sustituidas. | |
| PH12021552482A1 (en) | Compounds targeting prmt5 | |
| MX2024000299A (es) | Compuestos antivirales. | |
| PH12019501688B1 (en) | Pyridine derivative as ask1 inhibitor and preparation method and use thereof | |
| PH12021552805A1 (en) | Cdk inhibitors | |
| PH12021550825A1 (en) | Quinoline derivatives as alpha4beta7 integrin inhibitors | |
| MX2020001235A (es) | Análogos de 1,2-dihidro-3h-pirazolo[3,4-d]pirimidin-3-ona. | |
| ZA202308002B (en) | Pyrimidopyran compound | |
| ZA202401684B (en) | Novel parp7 inhibitor and use thereof | |
| ZA202007566B (en) | 2,3-dihydro-1h-pyrrolizine-7-formamide derivative and application thereof | |
| PH12020550905A1 (en) | Process for preparing antihelmintic 4-amino-quinoline-3-carboxamide derivatives | |
| WO2020210320A8 (en) | Substituted 1,2-dihydro-3h-pyrazolo[3,4-d]pyrimidin-3-ones | |
| MX2023004102A (es) | Derivado de gamma-carbolina fusionado sustituido con heterociclo, metodo de preparacion del mismo, intermediarios del mismo y uso del mismo. | |
| PH12021552513A1 (en) | Pyrrole compounds | |
| MX2020008816A (es) | Derivados de triazina para el tratamiento de enfermedades relacionadas con neurotrofinas. | |
| CR20240014A (es) | Pirimidinil-pirazoles sustituidos como inhibidores de cdk2 | |
| MX2025013480A (es) | Compuestos heterocíclicos que contienen nitrógeno y uso de los mismos | |
| ZA202307945B (en) | Pyridopyrimidinone derivative, preparation method therefor, and use thereof | |
| TN2021000025A1 (en) | Novel heterocyclic amine derivative and pharmaceutical composition comprising same | |
| MX2023001275A (es) | Inhibidores de raf biciclicos fusionados y metodos para su uso. | |
| MX2022010957A (es) | Compuestos que se dirigen a las proteínas de unión al arn o a las proteínas modificadoras del arn. | |
| PH12021552953A1 (en) | Tricyclic compounds |